The 'King of Biotech' reaches SEC settlement pact; Sanofi gets positive new data on Fluzone;

@FierceBiotech: Rigel shares slide after another drug flops in PhII asthma study. Story | Follow @FierceBiotech

@JohnCFierce: Two years ago Rigel was celebrating when Pfizer turned over R343. Now enthusiasm likely dimmed as top 2 drugs are under a dark cloud. | Follow @JohnCFierce

@EmilyMFierce: High copper levels implicated in Alzheimer's disease. Story | Follow @EmilyMFierce

> David Blech, once known in some circles as the "King of Biotech," has reached a settlement deal with the SEC regarding charges of market manipulation of shares of Pluristem Therapeutics ($PSTI) and Intellect Neurosciences. Story

> Sanofi ($SNY) is touting new data on patients 65 and older for its high-dose version of Fluzone. Story

Medical Device News

@FierceMedDev: Sign up for our new publication, FierceDiagnostics, launching with its first weekly newsletter this Wednesday. Sign up | Follow @FierceMedDev

@DamianFierce: CROs are dishing out more and more bonuses to quell sky-high turnover rates, according to a study. Report | Follow @DamianFierce

@MarkHFierce: Thermo Fisher is rolling out a major scholarship program for science/math students at elite universities. Smart. Release | Follow @MarkHFierce

@MichaelGFierce: Zimmer lands FDA clearance for 3-D surgical system. Article | Follow @MichaelGFierce

> Medtronic fails to stop patient's Infuse lawsuit. News

> Investment bank launches healthcare-focused crowdfunding option. Item

Pharma News

@FiercePharma: Japan's budget-minded PM wants to open universal health system to more add-on treatments. Could boost cancer meds. Article | Follow @FiercePharma

@EricPFierce: Australia to track Yervoy patients to see if it's worth the $110K price. More | Follow @EricPFierce

@CarlyHFierce: Ex-Novartis chair Vasella considers his results worth the once-approved $78M payout--will make $5.2M instead. Story Follow @CarlyHFierce

> Australia to track Yervoy patients to see if it's worth the $110K price. News

> Sanofi eyes superiority claim for Fluzone High-Dose after trial boost. More

CRO News

> U.K. outfit bets on early-phase outsourcing. News

> CRO Psi jumps into India. More

> Vince & Associates eyes gastro trials with expansion. Article

> Study: CROs dishing out bonuses to halt high turnover. Story

> Icon dives into adaptive trial monitoring. News

Biotech IT News

> Capgemini taps Amazon cloud for Big Data analytics. Story

> Harvard-MIT collaboration adds Lego-like genome analysis tool. Article

> Google bolsters security of cloud data storage service. More

> FDA pilot project ups benefits of IT supply chain investments. News

> EMA to start accepting digital signatures next month. Story

And Finally… Investigators at Johns Hopkins say they have identified a new target for drug developers focused on Parkinson's disease. "Not only were we able to identify the mechanism that could cause progressive cell death in both inherited and non-inherited forms of Parkinson's, we found there were already compounds in existence that can cross into the brain and block this from happening," says Johns Hopkins' Valina Dawson. Release